For: | Rubio MG, Amo-Mensah K, Gray JM, Nguyen VQ, Nakat S, Grider D, Love K, Boone JH, Sorrentino D. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol 2019; 10(5): 54-63 [PMID: 31911845 DOI: 10.4291/wjgp.v10.i5.54] |
---|---|
URL: | https://www.wjgnet.com/1948-5190/full/v10/i5/54.htm |
Number | Citing Articles |
1 |
Filippo Vernia, Angelo Viscido, Mirko Di Ruscio, Gianpiero Stefanelli, Marco Valvano, Giovanni Latella. Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn’s Disease: Do They Still Have a Potential Clinical Role?. Digestion 2021; 102(6): 833 doi: 10.1159/000518419
|
2 |
Chiara Rocchi, Youssef Y. Soliman, Marco Massidda, Salvatore F. Vadalà di Prampero, Milutin Bulajic, Dario Sorrentino. Is Ustekinumab Effective in Refractory Crohn’s Disease of the Pouch and Chronic Pouchitis? A Systematic Review. Digestive Diseases and Sciences 2022; 67(6): 1948 doi: 10.1007/s10620-021-07002-5
|
3 |
Malwina Naghibi, Adria Pont-Beltran, Araceli Lamelas, Laura Llobregat, Juan Martinez-Blanch, Antonia Rojas, Beatriz Álvarez, Bricia López Plaza, Lucia Arcos Castellanos, Empar Chenoll, Vineetha Vijayakumar, Richard Day. Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study. Nutrients 2024; 16(22): 3952 doi: 10.3390/nu16223952
|
4 |
Gabriele Dragoni, Tommaso Innocenti, Andrea Galli. Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?. Digestive Diseases 2021; 39(3): 190 doi: 10.1159/000511641
|
5 |
Michał Sienkiewicz, Andrzej Jaśkiewicz, Aleksandra Tarasiuk, Jakub Fichna. Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance. Critical Reviews in Food Science and Nutrition 2022; 62(22): 6016 doi: 10.1080/10408398.2021.1895063
|
6 |
舒 陈. Progress in Biomarkers of Inflammatory Bowel Disease. Advances in Clinical Medicine 2024; 14(03): 1418 doi: 10.12677/acm.2024.143860
|
7 |
James M. Gray, Kristin Knight, Vu Q. Nguyen, Marrieth G. Rubio, Lauren Irby, James H. Boone, Dario Sorrentino. Fecal Lactoferrin and Other Stool Markers during Normal Pregnancy and in Inflammatory Bowel Diseases: A Prospective Study and Review of the Literature. Inflammatory Intestinal Diseases 2020; 5(3): 151 doi: 10.1159/000508970
|
8 |
Antimo Cutone, Giusi Ianiro, Maria Stefania Lepanto, Luigi Rosa, Piera Valenti, Maria Carmela Bonaccorsi di Patti, Giovanni Musci. Lactoferrin in the Prevention and Treatment of Intestinal Inflammatory Pathologies Associated with Colorectal Cancer Development. Cancers 2020; 12(12): 3806 doi: 10.3390/cancers12123806
|
9 |
Xiaolin Sheng, Dandan Liu, Sujani K. Gamage, Ying Luo, Emilie Viennois, Didier Merlin, Suri S. Iyer. Point-of-Care Monitoring of Colitis Using Intestinal Alkaline Phosphatase in Inflammatory Bowel Disease. ACS Sensors 2021; 6(3): 698 doi: 10.1021/acssensors.0c02177
|
10 |
Dario Sorrentino, Vu Q. Nguyen, Kim Love. Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease. Digestive Diseases 2021; 39(6): 626 doi: 10.1159/000515432
|
11 |
E. V. Bolotova, K. A. Yumukyan, A. V. Dudnikova. New Diagnostic Possibilities for Determining the Activity of Ulcerative Colitis: The Role of Neutrophils. The Russian Archives of Internal Medicine 2022; 12(4): 285 doi: 10.20514/2226-6704-2022-12-4-285-292
|
12 |
Loren Galler Rabinowitz, Stephanie Lauren Gold, Elana A. Maser. Management of Inpatient Inflammatory Bowel Disease. 2022; : 31 doi: 10.1007/978-1-0716-1987-2_3
|
13 |
Dario Sorrentino, James M Gray. Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2021; 27(8): 1237 doi: 10.1093/ibd/izaa348
|
14 |
Rebecca L. Smith, Kirstin M. Taylor, Antony B. Friedman, David J. Gibson, Danny Con, Peter R. Gibson. Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 2022; 34(6): 613 doi: 10.1097/MEG.0000000000002367
|
15 |
Hairong Tang, Gongwei Sun, Ying Xu, Shasha Men, Wencan Jiang, Chengbin Wang. Simultaneous determination of inflammatory factors SAA and LTF based on stable element labeling and inductively coupled plasma mass spectrometry to aid in the diagnosis of infection. Journal of Immunological Methods 2024; 528: 113666 doi: 10.1016/j.jim.2024.113666
|
16 |
Liang-Fang Wang, Ping-Run Chen, Si-Ke He, Shi-Hao Duan, Yan Zhang. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World Journal of Gastroenterology 2023; 29(29): 4481-4498 doi: 10.3748/wjg.v29.i29.4481
Abstract(639) |
Core Tip(575) |
Full Article(HTML)(3114)
|
Full Article with Cover (PDF)-1082K(106)
|
Full Article (Word)-443K(42)
|
Audio-423K(10)
|
Peer-Review Report-263K(65)
|
Answering Reviewers-51K(58)
|
Supplementary Material-133K(73)
|
Full Article (PDF)-663K(249)
|
Full Article (XML)-417K(70)
|
Times Cited (3)
|
Total Visits (7401)
|
Open
|